Literature DB >> 1378342

Alpha 4-2 beta 2 and other nicotinic acetylcholine receptor subtypes as targets of psychoactive and addictive drugs.

J Connolly1, J Boulter, S F Heinemann.   

Abstract

1. Xenopus oocytes were injected with various muscle and neuronal nicotinic acetylcholine receptor (ACh receptor, cholinoceptor) subunit RNA combinations and their pharmacological properties studied using two-electrode voltage clamp. The functional expression of one of these combinations, rat alpha 4-2 beta 2, has not been previously described. The alpha 4-2 mRNA is a splicing variant transcribed from the alpha 4 gene. In the experiments reported here, the alpha 4-2 beta 2 subtype was functionally indistinguishable from the alpha 4-1 beta 2 subtype. 2. For each subtype, the relative potency of nicotine compared with acetylcholine was obtained by estimating the relative concentration of nicotine which would elicit the same current response as 0.1 microM Ach. The ratios of these concentrations (nicotine: ACh) for the mouse muscle ACh receptor-(alpha 1 beta 1 gamma delta) was 96.1:1. In contrast, the ratios for the rat neuronal subtypes were: alpha 2 beta 2, 1.01:1; alpha 3 beta 2, 2.01:1; alpha 4 beta 2, 0.76:1 and alpha 4-2 beta 2, 0.76:1. The much greater relative nicotine sensitivity of the neuronal subtypes as compared with muscle receptors illustrates their potential to mediate the psychoactive and addictive effects of nicotine. However, it does not appear that the differences in relative nicotinic sensitivity among the neuronal receptors themselves can be used as a simple discriminative tool in neuronal tissue. 3. The slopes of the log dose-log response curves at low ACh concentrations were all greater than 1 but less than 2, suggesting that at least two agonist binding sites mediate the functional response of each hetero-oligomer. 4. The response of all the neuronal subtypes to ACh could be inhibited by the psychoactive drugs mecamylamine, amitriptyline, phencyclidine, trifluoperazine and promethazine. With the exception of the very potent antagonist, mecamylamine, the degree of block of the peak current to ACh produced by 10 microM concentrations of these drugs was remarkably similar (around 50%). 5. The degree of inhibition produced when the antipsychotic drug, trifluoperazine, was co-applied with ACh increased as the duration of application increased. Such an effect was not observed with promethazine, a related phenothiazine derivative which does not have antipsychotic actions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378342      PMCID: PMC1908465          DOI: 10.1111/j.1476-5381.1992.tb09035.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  74 in total

1.  Immunohistochemical localization of neuronal nicotinic receptors in the rodent central nervous system.

Authors:  L W Swanson; D M Simmons; P J Whiting; J Lindstrom
Journal:  J Neurosci       Date:  1987-10       Impact factor: 6.167

Review 2.  Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction.

Authors:  N L Benowitz
Journal:  N Engl J Med       Date:  1988-11-17       Impact factor: 91.245

3.  Structure of the high-affinity binding site for noncompetitive blockers of the acetylcholine receptor: serine-262 of the delta subunit is labeled by [3H]chlorpromazine.

Authors:  J Giraudat; M Dennis; T Heidmann; J Y Chang; J P Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

4.  5-HT3 receptors mediate rapid responses in cultured hippocampus and a clonal cell line.

Authors:  J L Yakel; M B Jackson
Journal:  Neuron       Date:  1988-09       Impact factor: 17.173

5.  cDNA clones coding for the structural subunit of a chicken brain nicotinic acetylcholine receptor.

Authors:  R Schoepfer; P Whiting; F Esch; R Blacher; S Shimasaki; J Lindstrom
Journal:  Neuron       Date:  1988-05       Impact factor: 17.173

6.  Neuronal nicotinic acetylcholine receptor beta-subunit is coded for by the cDNA clone alpha 4.

Authors:  P Whiting; F Esch; S Shimasaki; J Lindstrom
Journal:  FEBS Lett       Date:  1987-07-27       Impact factor: 4.124

7.  Structure of the high-affinity binding site for noncompetitive blockers of the acetylcholine receptor: [3H]chlorpromazine labels homologous residues in the beta and delta chains.

Authors:  J Giraudat; M Dennis; T Heidmann; P Y Haumont; F Lederer; J P Changeux
Journal:  Biochemistry       Date:  1987-05-05       Impact factor: 3.162

8.  Reductions in acetylcholine and nicotine binding in several degenerative diseases.

Authors:  P J Whitehouse; A M Martino; K A Marcus; R M Zweig; H S Singer; D L Price; K J Kellar
Journal:  Arch Neurol       Date:  1988-07

9.  Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor.

Authors:  K Wada; M Ballivet; J Boulter; J Connolly; E Wada; E S Deneris; L W Swanson; S Heinemann; J Patrick
Journal:  Science       Date:  1988-04-15       Impact factor: 47.728

10.  Structurally different neuronal nicotinic acetylcholine receptor subtypes purified and characterized using monoclonal antibodies.

Authors:  P J Whiting; R Liu; B J Morley; J M Lindstrom
Journal:  J Neurosci       Date:  1987-12       Impact factor: 6.167

View more
  19 in total

1.  The role of the amino acid residue at alpha1:189 in the binding of neuromuscular blocking agents to mouse and human muscle nicotinic acetylcholine receptors.

Authors:  P G Purohit; R J Tate; E Pow; D Hill; J G Connolly
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

2.  Heterogeneity of neuronal nicotinic acetylcholine receptors in thin slices of rat medial habenula.

Authors:  J G Connolly; A J Gibb; D Colquhoun
Journal:  J Physiol       Date:  1995-04-01       Impact factor: 5.182

Review 3.  Functional architecture of the nicotinic acetylcholine receptor: a prototype of ligand-gated ion channels.

Authors:  A Devillers-Thiéry; J L Galzi; J L Eiselé; S Bertrand; D Bertrand; J P Changeux
Journal:  J Membr Biol       Date:  1993-11       Impact factor: 1.843

4.  Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats.

Authors:  Natashia Swalve; Steven T Pittenger; Rick A Bevins; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

5.  Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release.

Authors:  P B Clarke; M Reuben
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

6.  Behavioral adaptation in C. elegans produced by antipsychotic drugs requires serotonin and is associated with calcium signaling and calcineurin inhibition.

Authors:  Dallas R Donohoe; Raymond A Jarvis; Kathrine Weeks; Eric J Aamodt; Donard S Dwyer
Journal:  Neurosci Res       Date:  2009-04-05       Impact factor: 3.304

7.  alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues.

Authors:  C A Briggs; M R Schrimpf; D J Anderson; E J Gubbins; J H Grønlien; M Håkerud; H Ween; K Thorin-Hagene; J Malysz; J Li; W H Bunnelle; M Gopalakrishnan; M D Meyer
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

Review 8.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

9.  Low concentrations of amitriptyline inhibit nicotinic receptors in unmyelinated axons of human peripheral nerve.

Authors:  A Freysoldt; J Fleckenstein; P M Lang; D Irnich; P Grafe; R W Carr
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

Review 10.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.